Omeboix (Omeprazole)

Omeprazole, the active ingredient in Omeboix, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults and children. GNH USA supplies Omeboix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeboix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeboix (omeprazole) is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion. - Helicobacter pylori eradication regimens (as part of combination therapy): enhances eradication success when used with antibiotics. - Erosive esophagitis: promotes mucosal healing and symptom relief.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild cramping or discomfort. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Acute interstitial nephritis: kidney inflammation that may cause reduced urine output. - Severe hypersensitivity reactions: rash, itching, swelling, or anaphylaxis. - Osteoporosis‑related fractures: increased risk of hip, wrist or spine fractures with long‑term use. - Vitamin B12 deficiency: may develop after prolonged therapy. - Liver enzyme elevation: abnormal liver function tests indicating hepatic stress.

When using Omeboix, consider the following precautions: - Assess renal function: adjust use in patients with severe renal impairment. - Evaluate hepatic status: use cautiously in moderate to severe liver disease. - Review concomitant medications: consider potential drug‑drug interactions. - Monitor long‑term therapy: periodic assessment for bone health and vitamin B12 levels. - Pregnancy and lactation: weigh benefits against potential risks; prescribe only if clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Omeboix may interact with several medicines. Review the following interaction categories:

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atorvastatin: increased statin exposure, raising risk of myopathy. - Methotrexate: elevated methotrexile levels, potential toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer coagulation monitoring. - Digoxin: altered digoxin concentrations, necessitating serum level checks. - Phenytoin: decreased phenytoin levels, may reduce seizure control. - Ketoconazole: reduced azole absorption, diminishing antifungal efficacy.